WO2003089456A2 - Peptide inhibitors of protein kinase c - Google Patents

Peptide inhibitors of protein kinase c Download PDF

Info

Publication number
WO2003089456A2
WO2003089456A2 PCT/US2003/012541 US0312541W WO03089456A2 WO 2003089456 A2 WO2003089456 A2 WO 2003089456A2 US 0312541 W US0312541 W US 0312541W WO 03089456 A2 WO03089456 A2 WO 03089456A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
peptide
peptides
pkc
isozyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/012541
Other languages
English (en)
French (fr)
Other versions
WO2003089456A3 (en
Inventor
Daria Mochly-Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2003234185A priority Critical patent/AU2003234185C1/en
Priority to CA2482598A priority patent/CA2482598C/en
Priority to EP03728494A priority patent/EP1501532A4/en
Priority to JP2003586176A priority patent/JP2005523326A/ja
Priority to US10/513,003 priority patent/US7393835B2/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2003089456A2 publication Critical patent/WO2003089456A2/en
Publication of WO2003089456A3 publication Critical patent/WO2003089456A3/en
Anticipated expiration legal-status Critical
Priority to US11/879,414 priority patent/US7833984B2/en
Priority to AU2009201760A priority patent/AU2009201760B2/en
Priority to US13/101,540 priority patent/US8658594B2/en
Priority to US14/187,070 priority patent/US9365837B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Definitions

  • SEQ ID NO:51 is a fragment derived from SEQ ID N0.49.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
PCT/US2003/012541 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c Ceased WO2003089456A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2003234185A AU2003234185C1 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase C
CA2482598A CA2482598C (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c
EP03728494A EP1501532A4 (en) 2002-04-22 2003-04-22 PEPTIDE INHIBITORS OF PROTEIN KINASE C
JP2003586176A JP2005523326A (ja) 2002-04-22 2003-04-22 プロテインキナーゼｃのペプチドインヒビター
US10/513,003 US7393835B2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase C
US11/879,414 US7833984B2 (en) 2002-04-22 2007-07-16 Peptide inhibitors of protein kinase C
AU2009201760A AU2009201760B2 (en) 2002-04-22 2009-05-04 Peptide inhibitors of protein kinase C
US13/101,540 US8658594B2 (en) 2002-04-22 2011-05-05 Peptide inhibitors of protein kinase C
US14/187,070 US9365837B2 (en) 2002-04-22 2014-02-21 Peptide inhibitors of protein kinase C

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37453002P 2002-04-22 2002-04-22
US60/374,530 2002-04-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/421,503 Continuation US7507711B2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase C

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US10513003 A-371-Of-International 2003-04-22
US10/513,003 A-371-Of-International US7393835B2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase C
US11/879,414 Continuation US7833984B2 (en) 2002-04-22 2007-07-16 Peptide inhibitors of protein kinase C
US12/214,104 Continuation US7939493B2 (en) 2002-04-22 2008-06-16 Peptide inhibitors of protein kinase C

Publications (2)

Publication Number Publication Date
WO2003089456A2 true WO2003089456A2 (en) 2003-10-30
WO2003089456A3 WO2003089456A3 (en) 2004-02-12

Family

ID=29251202

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/012542 Ceased WO2003089457A2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c ϝ for pain management
PCT/US2003/012541 Ceased WO2003089456A2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/012542 Ceased WO2003089457A2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c ϝ for pain management

Country Status (6)

Country Link
US (8) US7393835B2 (enExample)
EP (3) EP1501533A4 (enExample)
JP (5) JP2005527209A (enExample)
AU (4) AU2003234186B2 (enExample)
CA (3) CA2482598C (enExample)
WO (2) WO2003089457A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035782A3 (en) * 2005-09-19 2007-10-25 Kai Pharmaceuticals Inc Protein kinase c peptide modulators of angiogenesis
JP2008526987A (ja) * 2005-01-14 2008-07-24 フィラデルフィア・カレッジ・オブ・オステオパシック・メディスン 臓器のための灌流及び／又は保存溶液
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
US9255124B2 (en) 2007-01-19 2016-02-09 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2482598C (en) 2002-04-22 2012-09-25 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
EP1631309A4 (en) * 2003-05-16 2010-04-28 Univ Leland Stanford Junior Protein kinase c peptides for use in withdrawal
AU2003264918A1 (en) * 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
US8133733B2 (en) * 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) * 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) * 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
CA2549052A1 (en) * 2003-12-11 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
EP1877424A4 (en) * 2005-04-11 2010-09-29 Pharmagap Inc INHIBITORS OF PROTEIN KINASES AND USES THEREOF
EP2298792A3 (en) 2005-08-05 2011-10-19 Pharmagap Inc. Peptides targeted to protein kinase C isoforms and uses thereof
WO2007025249A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
EP1998791A4 (en) * 2006-03-30 2009-11-04 Salpep Biotechnology Inc SUPPRESSION AND TREATMENT OF NEUROPATHIC PAIN
WO2007143119A2 (en) * 2006-06-01 2007-12-13 The Board Of Trustees Of The Leland Stanford Junior University Method of preventing progression of hypertension-induced heart failure with pkc peptides
EP2124987A4 (en) * 2007-01-19 2012-05-02 Kai Pharmaceuticals Inc METHOD OF USE OF EPSILON HEMMER COMPOUNDS FOR PAIN LIFTING
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
WO2008124698A2 (en) * 2007-04-06 2008-10-16 Kai Pharmaceuticals, Inc. Methods of use of gamma inhibitor compounds for the attenuation of pain
US20090137493A1 (en) * 2007-06-07 2009-05-28 Mochly-Rosen Daria D Inhibition of tumor metastases using protein kinase C (PKC) inhibitors
AU2008343841A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
MX2010010569A (es) * 2008-03-27 2010-11-04 Nestec Sa Metodos para incrementar la absorcion de peptidos, peptidomimeticos y otros sustratos de proteina de transporte gastrointestinal.
US20100048482A1 (en) * 2008-08-15 2010-02-25 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
CA2753208C (en) 2009-02-20 2018-08-21 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
KR101720961B1 (ko) * 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
CA2754482A1 (en) * 2009-03-06 2010-09-10 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
US20100311671A1 (en) * 2009-03-25 2010-12-09 Kai Pharmaceuticals Transdermal delivery of pkc modulatory peptides through microporated skin
EP2482837A4 (en) 2009-09-29 2013-05-22 Joslin Diabetes Center Inc USE OF PROTEIN KINASE C-DELTA (PKCD) INHIBITORS FOR THE TREATMENT OF DIABETES, ADIPOSITAS AND LIVER VARIATION
AU2011223563A1 (en) * 2010-03-05 2012-11-01 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
WO2013025525A1 (en) 2011-08-12 2013-02-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for specific regulation of pyruvate dehydrogenase kinase
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
WO2015039187A1 (en) 2013-09-18 2015-03-26 University Of Canberra Stem cell modulation ii
EP3185858A4 (en) 2014-08-25 2017-12-27 University of Canberra Compositions for modulating cancer stem cells and uses therefor
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
CN111587120A (zh) 2017-11-08 2020-08-25 艾比克斯治疗私人有限公司 免疫原性组合物及其用途
WO2021122641A1 (en) * 2019-12-16 2021-06-24 Sony Semiconductor Solutions Corporation Time-of-flight imaging circuitry, time-of-flight imaging system, time-of-flight imaging method
TW202146071A (zh) * 2020-03-31 2021-12-16 日商東麗股份有限公司 影像解析裝置、影像解析裝置的控制方法、影像解析系統、及影像解析系統的控制方法
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351829A (en) * 1980-09-26 1982-09-28 Farmitalia Carlo Erba Spa Use of polypeptides as analgesic drugs
ATE173016T1 (de) 1992-08-21 1998-11-15 Biogen Inc Von tat abgeleitete transportpolypeptide
US5776685A (en) * 1993-07-19 1998-07-07 Joslin Diabetes Center Protein kinase C assay
US5783405A (en) 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6218113B1 (en) 1998-02-24 2001-04-17 Incyte Genomics, Inc. Human protein kinase C inhibitor
ATE350032T1 (de) 1998-07-06 2007-01-15 Univ California Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
ATE276754T1 (de) * 1998-07-21 2004-10-15 Cytovia Inc Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
HK1039504A1 (zh) * 1998-09-14 2002-04-26 泛太平洋制药公司 蜂毒蛋白的有用特性和编码这种蜂毒蛋白的基因
CA2343934A1 (en) 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
GB9905218D0 (en) 1999-03-09 1999-04-28 Univ Glasgow Neurodegenerative disorder related gene
EP1234188A2 (en) * 1999-12-02 2002-08-28 The University of Dundee Protein kinase regulation
CN1300845A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人二酰基甘油蛋白激酶亚单位9和编码这种多肽的多核苷酸
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6496425B1 (en) * 2000-08-21 2002-12-17 Micron Technology, Inc Multiple bit line column redundancy
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
CA2482598C (en) 2002-04-22 2012-09-25 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526987A (ja) * 2005-01-14 2008-07-24 フィラデルフィア・カレッジ・オブ・オステオパシック・メディスン 臓器のための灌流及び／又は保存溶液
EP1845773A4 (en) * 2005-01-14 2011-08-17 Philadelphia College Of Osteopathic Medicine PERFUSION AND / OR CONVERSION SOLUTION FOR ORGANS
CN102763637A (zh) * 2005-01-14 2012-11-07 整骨疗法费城医学院 用于器官的灌注液和/或保存溶液
US9029078B2 (en) 2005-01-14 2015-05-12 Philadelphia College Of Osteopathic Medicine Perfusion and/or preservation solution for organs
WO2007035782A3 (en) * 2005-09-19 2007-10-25 Kai Pharmaceuticals Inc Protein kinase c peptide modulators of angiogenesis
AU2006292228B2 (en) * 2005-09-19 2013-02-21 Kai Pharmaceuticals, Inc. Protein kinase C peptide modulators of angiogenesis
US9255124B2 (en) 2007-01-19 2016-02-09 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US10077438B2 (en) 2007-01-19 2018-09-18 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
US9376423B2 (en) 2010-08-10 2016-06-28 The Regents Of The University Of California PKC-epsilon inhibitors
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors

Also Published As

Publication number Publication date
AU2009201593A1 (en) 2009-05-21
US20080167247A1 (en) 2008-07-10
JP2005527209A (ja) 2005-09-15
WO2003089457B1 (en) 2004-04-15
WO2003089457A2 (en) 2003-10-30
AU2003234185C1 (en) 2009-11-19
JP2005523326A (ja) 2005-08-04
AU2003234185B2 (en) 2009-02-05
US7939493B2 (en) 2011-05-10
US20030223981A1 (en) 2003-12-04
AU2009201760A1 (en) 2009-05-28
CA2482598C (en) 2012-09-25
US7507711B2 (en) 2009-03-24
CA2482598A1 (en) 2003-10-30
EP1501532A4 (en) 2007-11-14
JP2009102392A (ja) 2009-05-14
US9365837B2 (en) 2016-06-14
WO2003089456A3 (en) 2004-02-12
JP2012176978A (ja) 2012-09-13
EP2332559A1 (en) 2011-06-15
CA2481512A1 (en) 2003-10-30
US7459424B2 (en) 2008-12-02
US20090143293A1 (en) 2009-06-04
WO2003089457A3 (en) 2004-01-22
AU2009201593B2 (en) 2012-05-24
US7393835B2 (en) 2008-07-01
US20110275575A1 (en) 2011-11-10
CA2785889A1 (en) 2003-10-30
US20090192091A1 (en) 2009-07-30
EP1501532A2 (en) 2005-02-02
AU2003234185A1 (en) 2003-11-03
EP1501533A4 (en) 2007-10-31
US20040009922A1 (en) 2004-01-15
AU2003234186B2 (en) 2009-01-22
AU2003234186A1 (en) 2003-11-03
US20140178352A1 (en) 2014-06-26
AU2009201760B2 (en) 2011-03-17
US7833984B2 (en) 2010-11-16
US20050215483A1 (en) 2005-09-29
CA2481512C (en) 2013-06-18
JP2009091372A (ja) 2009-04-30
US8658594B2 (en) 2014-02-25
EP1501533A2 (en) 2005-02-02

Similar Documents

Publication Publication Date Title
US7393835B2 (en) Peptide inhibitors of protein kinase C
EP1351980B1 (en) Peptides for activation and inhibition of delta pkc
AU2002226061A1 (en) Peptides for activation and inhibition of delta PKC
US7544654B2 (en) ψεRACK peptide composition and method for protection against tissue damage due to ischemia
AU2011202912A1 (en) Peptide inhibitors of protein kinase C
AU2001297950B2 (en) psi-epsilon RACK peptide composition and method for protection against tissue damage due to ischemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003234185

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2482598

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003586176

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003728494

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003728494

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10513003

Country of ref document: US